

FOR IMMEDIATE RELEASE

January 26, 2007

**Astellas and Pfizer Reached Settlement
on Declaratory Judgment Action relating to Lipitor Agreement**

Tokyo, January 26, 2007 – Pfizer Japan Inc. (“Pfizer”) and Astellas Pharma Inc. (“Astellas”) announced that a settlement has been reached today by Pfizer, Pfizer’s affiliate, and Astellas, which are the parties to a Development and Marketing Agreement for a hypercholesterolemia drug “Lipitor®” manufactured and distributed by Astellas and promoted jointly by Pfizer and Astellas in Japan (the “DMA”) on a declaratory judgment action filed by Astellas to confirm that the term of DMA shall continue until July 8, 2016.

The action was filed by Astellas on November 7, 2006 at the Tokyo District Court.

The settlement agreement contains the following conditions:

- The DMA is amended to the effect that the term of DMA will expire on July 8, 2016.
- All other terms and conditions of the DMA will remain unchanged.
- Astellas will withdraw the declaratory judgment action.

The settlement involves no payment from either party to the other.

Pfizer and Astellas are pleased with the prompt resolution of this issue, and are committed to the marketing and promotion of Lipitor in Japan with a renewed focus.

#####

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com
Pfizer Japan Inc. Corporate Communications Tel: +81-3-5309-7201 Fax: +81-3-5309-9004 http://www.pfizer.co.jp